Literature DB >> 23136115

Desirable attributes of vaccines for deployment in low-resource settings.

Dexiang Chen1, Darin Zehrung.   

Abstract

A number of product development partnerships are actively developing new vaccines to combat infectious diseases in developing countries. To be effective, the products under development should not only be safe, efficacious, and affordable, but they should also have additional desirable technical attributes, including enhanced stability, efficient packaging, and improved ease of delivery. New technologies are now available to achieve these attributes; however, many of the technologies have yet to be adopted by the vaccine industry. This commentary discusses the opportunities and challenges associated with advancing such attributes, especially vaccine thermostability and dose sparing strategies, and the critical issues that must be addressed to bridge the gap between technology development and product development.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23136115     DOI: 10.1002/jps.23352

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.

Authors:  Xueting Wang; Ning Wang; Ning Li; Yuanyuan Zhen; Ting Wang
Journal:  Hum Vaccin Immunother       Date:  2016-05-09       Impact factor: 3.452

2.  Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Authors:  Mark T Orr; Ryan M Kramer; Lucien Barnes; Quinton M Dowling; Anthony L Desbien; Elyse A Beebe; John D Laurance; Christopher B Fox; Steven G Reed; Rhea N Coler; Thomas S Vedvick
Journal:  J Control Release       Date:  2013-12-29       Impact factor: 9.776

3.  Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Authors:  Ryan M Kramer; Michelle C Archer; Mark T Orr; Natasha Dubois Cauwelaert; Elyse A Beebe; Po-Wei D Huang; Quinton M Dowling; Alicia M Schwartz; Dawn M Fedor; Thomas S Vedvick; Christopher B Fox
Journal:  Int J Nanomedicine       Date:  2018-06-26

Review 4.  Nanoengineering of vaccines using natural polysaccharides.

Authors:  Ana Sara Cordeiro; María José Alonso; María de la Fuente
Journal:  Biotechnol Adv       Date:  2015-06-03       Impact factor: 14.227

5.  A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery.

Authors:  Alana Gerhardt; Emily Voigt; Michelle Archer; Sierra Reed; Elise Larson; Neal Van Hoeven; Ryan Kramer; Christopher Fox; Corey Casper
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-16       Impact factor: 6.698

6.  A Safe and Stable Neonatal Vaccine Targeting GAPDH Confers Protection against Group B Streptococcus Infections in Adult Susceptible Mice.

Authors:  Joana Alves; Pedro Madureira; Maria Teresa Baltazar; Leandro Barros; Liliana Oliveira; Ricardo Jorge Dinis-Oliveira; Elva Bonifácio Andrade; Adília Ribeiro; Luís Mira Vieira; Patrick Trieu-Cuot; José Alberto Duarte; Félix Carvalho; Paula Ferreira
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.